Loading...
XNASETON
Market cap380mUSD
Jan 15, Last price  
14.30USD
1D
6.56%
1Q
70.24%
IPO
138.33%
Name

Eton Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ETON chart
P/E
—
P/S
12.04
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.92%
Rev. gr., 5y
-54.82%
Revenues
32m
+48.90%
00959,00039,00021,832,00021,251,00031,642,000
Net income
-936k
L-90.43%
-7,156,000-12,740,000-18,039,000-28,829,000-2,961,000-9,782,000-936,000
CFO
7m
+41.36%
-4,718,000-8,145,000-18,026,000-22,346,000-4,721,0004,821,0006,815,000
Earnings
Jun 11, 2025

Profile

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
URL
https://etonpharma.com/
IPO date
Nov 09, 2018
Employees
28
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
31,642
48.90%
21,251
-2.66%
Cost of revenue
32,834
29,511
Unusual Expense (Income)
NOPBT
(1,192)
(8,260)
NOPBT Margin
Operating Taxes
247
761
Tax Rate
NOPAT
(1,439)
(9,021)
Net income
(936)
-90.43%
(9,782)
230.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
198
251
BB yield
-0.18%
-0.35%
Debt
Debt current
5,380
1,033
Long-term debt
44
5,598
Deferred revenue
Other long-term liabilities
Net debt
(15,964)
(9,674)
Cash flow
Cash from operating activities
6,815
4,821
CAPEX
(775)
(2,788)
Cash from investing activities
(775)
(2,788)
Cash from financing activities
(957)
(134)
FCF
(1,329)
(3,004)
Balance
Cash
21,388
16,305
Long term investments
Excess cash
19,806
15,242
Stockholders' equity
(104,044)
(103,109)
Invested Capital
124,923
122,711
ROIC
ROCE
EV
Common stock shares outstanding
25,645
25,146
Price
4.38
55.32%
2.82
-34.27%
Market cap
112,327
58.40%
70,912
-34.42%
EV
96,363
61,238
EBITDA
(291)
(6,486)
EV/EBITDA
Interest
761
Interest/NOPBT